Page last updated: 2024-11-11

ritobegron

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9820882
CHEMBL ID2107773
SCHEMBL ID1404071
MeSH IDM0579101

Synonyms (18)

Synonym
ritobegron
unii-ld86rkr53m
255734-04-4
2-(4-(2-((2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)-2,5-dimethylphenyloxy)acetic acid
ritobegron [inn]
kuc-7322
ld86rkr53m ,
(4-(2-(((1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)amino)ethyl)-2,5-dimethylphenoxy)acetic acid
CHEMBL2107773
SCHEMBL1404071
AKOS030574948
DB12080
2-(4-(2-(((1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)amino)ethyl)-2,5-dimethylphenoxy)acetic acid
Q27282934
HY-116169
2-[4-[2-[[(1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]-2,5-dimethylphenoxy]acetic acid
DTXSID50870290
CS-0064266

Research Excerpts

Actions

ExcerptReferenceRelevance
"Ritobegron may increase the plasma concentrations of P-glycoprotein substrates, such as digoxin, and the plasma concentration of KUC-7322 may increase when it is administered in combination with OAT inhibitors such as probenecid."( Species differences in the metabolism of ritobegron in vitro and assessment of potential interactions with transporters and cytochrome P450 enzymes.
Abe, Y; Endo, T; Harada, H; Kanazawa, T; Kanbe, H; Kobayashi, M; Kojima, Y; Murakami, M; Ota, E, 2015
)
1.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" Twelve healthy men were administered a single oral dose of ritobegron (20 mg) alone or in combination with probenecid 2 hours before administration of ritobegron."( Investigation of Drug-Drug Interactions Between Ritobegron, a Selective β3 -Adrenoceptor Agonist, With Probenecid in Healthy Men.
Abe, Y; Endo, T; Furihata, T; Kanazawa, T; Kobayashi, M; Nakano, Y, 2016
)
0.93

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of KUC-7322 was estimated to be 4%."( Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats.
Abe, Y; Endo, T; Kobayashi, M; Murakami, M; Ota, E, 2014
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1238589Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as increase in mean blood pressure at 3 mg/kg, iv measured for 30 mins relative to control2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1238587Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as increase in heart rate at 3 mg/kg, iv measured for 30 mins relative to control2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1238590Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as decrease in mean blood pressure at 3 mg/kg, iv measured for 30 mins relative to control2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
AID1238588Cardiotoxicity in anesthetized Sprague-Dawley rat assessed as decrease in heart rate at 3 mg/kg, iv measured for 30 mins relative to control2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.66 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-blinded, Randomised, Placebo Controlled, Five-way Crossover Study With One Positive Control (Open-label) (Moxifloxacin) to Assess the Influence of Oral Single Dose KUC 7483 BS (40 mg, 80 mg, 160 mg, 320 mg) on the QT/QTc Interval of the ECG in He [NCT02256735]Phase 139 participants (Actual)Interventional2005-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]